J
Jason K. Perry
Researcher at D. E. Shaw Research
Publications - 53
Citations - 9781
Jason K. Perry is an academic researcher from D. E. Shaw Research. The author has contributed to research in topics: Polymerase & RNA. The author has an hindex of 22, co-authored 42 publications receiving 7917 citations.
Papers
More filters
Journal ArticleDOI
Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.
Richard A. Friesner,Jay L. Banks,Robert B. Murphy,Thomas A. Halgren,Jasna Klicic,Daniel T. Mainz,Matthew P. Repasky,Eric H. Knoll,Mee Shelley,Jason K. Perry,David E. Shaw,Perry Francis,Peter S Shenkin +12 more
TL;DR: Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand to find the best docked pose using a model energy function that combines empirical and force-field-based terms.
Journal ArticleDOI
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses
Dustin Siegel,Hui Hon Chung,Edward Doerffler,Michael O'neil Hanrahan Clarke,Kwon Soo Chun,Lijun Zhang,Sean Neville,Ernest Carra,Willard Lew,Bruce Ross,Queenie Wang,Lydia Wolfe,Robert Jordan,Veronica Soloveva,John E. Knox,Jason K. Perry,Michel Perron,Kirsten M. Stray,Ona Barauskas,Joy Y. Feng,Yili Xu,Gary Lee,Arnold L. Rheingold,Adrian S. Ray,Roy Bannister,Robert G. Strickley,S. Swaminathan,William A. Lee,Sina Bavari,Tomas Cihlar,Michael K. Lo,Travis K. Warren,Richard L. Mackman +32 more
TL;DR: A robust diastereoselective synthesis provided sufficient quantities of 4b to enable preclinical efficacy in a non-human-primate EBOV challenge model and structure activity relationships established that the 1′-CN group and C-linked nucleobase were critical for optimal anti-EBOV potency and selectivity against host polymerases.
Journal ArticleDOI
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.
Andrea J. Pruijssers,Andrea J. Pruijssers,Amelia S. George,Amelia S. George,Alexandra Schäfer,Sarah R. Leist,Lisa E. Gralinksi,Kenneth H. Dinnon,Boyd Yount,Maria L. Agostini,Maria L. Agostini,Laura J. Stevens,Laura J. Stevens,James D. Chappell,James D. Chappell,Xiaotao Lu,Xiaotao Lu,Tia M. Hughes,Tia M. Hughes,Kendra Gully,David R. Martinez,Ariane J. Brown,Rachel L. Graham,Jason K. Perry,Venice Du Pont,Jared Pitts,Bin Ma,Darius Babusis,Eisuke Murakami,Joy Y. Feng,John P. Bilello,Danielle P. Porter,Tomas Cihlar,Ralph S. Baric,Mark R. Denison,Mark R. Denison,Timothy P. Sheahan +36 more
TL;DR: Remdesivir (RDV) potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures and in mice infected with chimeric virus, supporting its further clinical testing for treatment of COVID-19.
Journal ArticleDOI
Structural basis for RNA replication by the hepatitis C virus polymerase.
Todd Appleby,Jason K. Perry,Eisuke Murakami,Ona Barauskas,Joy Y. Feng,Aesop Cho,David A. Fox,Diana R. Wetmore,Mary E. McGrath,Adrian S. Ray,Michael J. Sofia,S. Swaminathan,Thomas E. Edwards +12 more
TL;DR: The details of HCV RNA replication are studied by determining crystal structures of stalled polymerase ternary complexes with enzymes, RNA templates, RNA primers, incoming nucleotides, and catalytic metal ions during both primed initiation and elongation of RNA synthesis.
Journal ArticleDOI
Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection
John O. Link,James G. Taylor,Lianhong Xu,Michael L. Mitchell,Hongyan Guo,Hongtao Liu,Kato Darryl,Thorsten Kirschberg,Jianyu Sun,Neil H. Squires,Jay P. Parrish,Terry Kellar,Yang Zheng-Yu,Chris Yang,Mike Matles,Yujin Wang,Kelly Wang,Guofeng Cheng,Yang Tian,Erik Mogalian,Elsa Mondou,Melanie Cornpropst,Jason K. Perry,Manoj C. Desai +23 more
TL;DR: Compound 39 (ledipasvir, GS-5885) has an extended plasma half-life of 37-45 h in healthy volunteers and produces a rapid >3 log viral load reduction in monotherapy at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients.